BCL2 and acute myeloid leukemia: Idasanutlin is now being investigated in in a phase 1b/2 trial in combination with the Bcl-2 inhibitor venetoclax in relapsed/refractory AML (Clinicaltrials.gov identifier NCT02670044) based on preclinical studies which demonstrated a synergistic effect (84).